BioLife Obtains an American Patent for an Unprecedented Technology of Oral Administration of Peptides in Effervescent Form
4 Articles
4 Articles
Biolife granted U.S. patent for novel effervescent oral peptide delivery technology
BioLife today announced that the United States Patent and Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel effervescent oral peptide delivery technology, designed to support current and future peptide therapeutics for obesity, diabetes and metabolic disease.
PARIS-(BUSINESS WIRE)-Sep 10, 2026-
Preclinical studies demonstrated measurable systemic exposure to semaglutide after oral administration; the granted patent claims cover semaglutide and various GLP-1 receptor agonists. PARIS–(BUSINESS WIRE)– BioLife announced today that the United States Patent & Trademark Office has granted U.S. Patent 12,667,605 B2 for its novel technology for effervescent oral administration of peptides, designed to current and […]
Coverage Details
Bias Distribution
- 67% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
